MAAB Group Expands Global Healthcare Footprint Through Strategic Partnership with The Reflux Company

MAAB Group is pleased to announce its strategic partnership with The Reflux Company, alongside participation in its recently completed oversubscribed seed funding round.

This collaboration marks an important milestone in MAAB’s continued expansion into innovative global healthcare technologies, and represents our first strategic engagement in the United States.

A Unified Platform for Reflux Care

The Reflux Company is building a unique global platform focused exclusively on the diagnosis and treatment of reflux-related diseases, including Laryngopharyngeal Reflux (LPR) and Gastroesophageal Reflux Disease (GERD).

With a portfolio that spans:

• Advanced diagnostic tools (Dx-pH™)

• Minimally invasive therapies (Stretta®)

• Patient-centric solutions (Reflux Band®, PepsinCheck™)

the company is positioned to address a global patient population exceeding 1 billion individuals.

MAAB’s Role: From Capital to Commercialisation

Under this partnership, MAAB Group has been appointed as the official advisory service for Asia, with a primary focus on China.

MAAB will support The Reflux Company across several key strategic areas:

• Market Access & Regulatory Strategy

• Commercialisation & Distribution Network Development

• Strategic Partnerships in China

• Ongoing Fundraising and Expansion Initiatives

This reflects MAAB’s core capability — bridging innovative global healthcare technologies with complex, high-growth markets through structured localisation and execution.

Unlocking the China Opportunity

China represents one of the largest and fastest-growing markets for reflux diagnosis and treatment, yet remains significantly underpenetrated in terms of integrated diagnostic and therapeutic solutions.

MAAB’s established infrastructure and partnerships in China uniquely position us to:

• Accelerate product registration and market entry

• Build sustainable distribution networks

• Navigate regulatory complexity

• Align global innovation with local clinical practice

This partnership reinforces MAAB’s long-term strategy of building scalable healthcare platforms in Asia through selective investment and deep operational involvement.

A Strategic Step Forward for MAAB

“This collaboration reflects our conviction in the global potential of The Reflux Company,” said Alex Lou, Managing Director of MAAB Group.

“Their integrated portfolio provides a compelling solution for both diagnosis and treatment, and aligns strongly with our strategy of introducing high-impact, clinically differentiated technologies into Asia.”

Looking Ahead

As MAAB continues to expand its global footprint, this partnership highlights our commitment to:

• Identifying high-quality, scalable healthcare innovations

• Supporting companies beyond capital — into real market execution

• Building long-term value across cross-border healthcare ecosystems

Together with The Reflux Company, MAAB looks forward to unlocking new opportunities across Asia and bringing advanced reflux care solutions to patients worldwide.